BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
금요일, 9월 25

Prime Medicine Inc

PRMENASDAQ
Trade with Public
Trade with Public
$3.07
-0.06-1.92%
가까이에: Sep 24, 5:00 PM EST
$3.43
0.3611.73%
시간외: 7:59 PM EST
PRO
변동 이유?:Prime Medicine shares are trading higher after the company announced the FD...
개요뉴스실적 전망이벤트목표가재무심리지분 현황배당금비교옵션주식 보고서

Prime Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Prime Medicine (PRME).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

2S.Buy
9Buy
2Hold
Consensus RatingOutperform# Analysts13Avg. Consensus PT$10Upside to Avg. PT+201.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026Chardan CapitalKeay NakaeMaintainedBuy$7
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
Benzinga Newsdesk

This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgraded Warner Bros Discovery Inc with price targets.
Avi Kapoor

PRO
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.
Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6

LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved